Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc., and Adaptimmune Therapeutics plc, have entered into a co-development and co-commercialization agreement to develop new stem-cell derived allogeneic T-cell therapies to treat cancer. Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in preclinical or clinical trials or those deve...